Inivata is a Leader in Liquid Biopsy

Unlocking essential genomic information from a simple
blood draw to transform the care of cancer patients

Inivata is a Leader in Liquid Biopsy

Unlocking essential genomic information from a simple
blood draw to transform the care of cancer patients

Liquid Biopsy Unlocking essential genomic information from a simple blood draw to transform the care of cancer patients

InVision® platform

Our InVision® platform unlocks essential genomic information from a simple blood draw to transform the care of cancer patients

InVisionFirst®Lung Our US Medicare-reimbursed lead product InVisionFirst®Lung is already transforming the lives of advanced NSCLC patients

InVisionFirst®Lung

Our US Medicare-reimbursed lead product InVisionFirst®Lung is already transforming the lives of advanced NSCLC patients

Radar™  A multi-tumor assay for the detection of residual disease and recurrence based on the InVision® liquid biopsy platform

Radar

A multi-tumor assay for the detection of residual disease and recurrence based on the InVision® liquid biopsy platform

Our Mission

We are transforming the lives of cancer patients and their families through the power of liquid biopsy

InvisionFirst Lung - ctDNA Liquid Biopsy Test

Our Technology - Liquid Biopsy Testing

Our Technology

Contact Us at Inivata

Contact Us

Latest News and Events

Inivata Raises $35 million in Second Close of Series C Financing

Funds will accelerate clinical development of RaDaR minimal residual disease assay and commercialization of InVisionFirst®-Lung Read More

Circulating tumor DNA (ctDNA) clearance as a biomarker in patients with locally advanced NSCLC following chemoradiation

B. Knapp, L. Mezquita, S. Devarakonda, M. Aldea, S. Waqar, K. Pepin, J. Ward, A. Botticella, K. Howarth, C. Knape, C. Morris, R. ... Read More

Clinical Biomarkers & World CDx Europe 2021

Clinical Biomarkers & World CDx Europe 2021

Event expiration date display - 24 - 25 MAR 2021

Location: Online Event Read More

Changing Lives

Patients are at the heart of everything we do.

Our first product is for advanced Non-Small Cell lung Cancer and our world-leading tests are already impacting patients’ lives. 

This is the story of the first patient Inivata tested.

Transforming the lives of Cancer Patients and Their Families

As a dynamic and innovative company, we focus on the development of ground-breaking technology in a fast-paced and international setting.

Our team of talented and driven individuals work together to combine their energy and expertise in world-class research, product development and commercialization. Join us.

Our InVisionFirst-Lung #LiquidBiopsy test is being used in the Ph II ALKALINE trial, supported by @Pfizer and sponsored by the @EORTC, to help clinicians unlock accurate #insights about #patient responses to treatment.

Read more: http://bit.ly/35YLLnX #NSCLC #LungCancer

Have you read the latest #blog from Yanin Naiyachit, Product Manager – #LiquidBiopsy Applications, at Inivata? He discusses his experience at the recent LBx Precision Oncology Summit 2021: http://bit.ly/3us7sYb
#PrecisionOncology

Yanin Naiyachit, Product Manager – #LiquidBiopsy Applications here at #Inivata, discusses his key thoughts and take-aways from the recent LBx Precision Oncology Summit 2021, in his new #blog: https://bit.ly/3us7sYb

#Conference #ctDNA #PrecisionOncology #MRD